{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:17Z","timestamp":1793813897150,"version":"4.6.1"},"reference-count":28,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2019R1F1A1050774"],"award-info":[{"award-number":["NRF-2019R1F1A1050774"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>This study evaluated the possibility of clinical remission suggested by the treat-to-target strategy and identified predictors of clinical remission in 139 patients with ankylosing spondylitis (AS) receiving tumor necrosis factor-\u03b1 inhibitors (TNFi). Clinical remission criteria selected were AS Disease Activity Score Inactive Disease (ASDAS-ID) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) &lt; 2 with normal C-reactive protein (CRP) levels (BASDAI-CRP). The longitudinal relationship between clinical parameters and clinical remission was assessed using generalized estimating equations (GEEs). Responders to ASDAS-ID and BASDAI-CRP increased from 32.4% to 68.9% and from 39.9% to 75.2% at months 3 and 33, respectively. Responders to ASDAS-ID and BASDAI-CRP almost overlapped. In the univariable GEE model, age and 3-month improvement in BASDAI, ASDAS-CRP, physician and patient global assessments, and spinal pain predicted clinical remission achievement, while the presence of syndesmophytes predicted ASDAS-CRP achievement, and normalized CRP at 3 months was associated with BASDAI-CRP achievement. Multivariable GEE analysis revealed age (odds ratio (OR): 0.67; 95% confidence interval (CI), 0.49\u20130.93) and 3-month BASDAI improvement (OR: 1.70; CI, 1.19\u20132.41) as independent predictors of ASDAS-ID achievement and age (OR: 0.69; CI, 0.54\u20130.89), 3-month BASDAI improvement (OR: 2.00; CI, 1.45\u20132.76), and normalized CRP at 3 months (OR: 3.72; CI, 1.39\u20139.95) as independent predictors of BASDAI-CRP achievement.<\/jats:p>","DOI":"10.3390\/jcm10184279","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T08:04:23Z","timestamp":1632211463000},"page":"4279","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early Improvements in Disease Activity Indices Predict Long-Term Clinical Remission Suggested by the Treat-to-Target Strategy in Patients with Ankylosing Spondylitis Receiving TNF-\u03b1 Inhibitor Treatment"],"prefix":"10.3390","volume":"10","author":[{"given":"Eon Jeong","family":"Nam","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 41404, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Kee","family":"Lee","sequence":"additional","affiliation":[{"name":"Medical Research Collaboration Center, School of Medicine, Kyungpook National University, Daegu 41944, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/1744666X.2016.1218761","article-title":"An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis","volume":"13","author":"Osman","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.berh.2019.01.014","article-title":"Emerging treatment options for spondyloarthritis","volume":"32","author":"Torgutalp","year":"2018","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/acr.22708","article-title":"American College of Rheumatology\/Spondylitis association of america\/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"68","author":"Ward","year":"2016","journal-title":"Arthritis Care Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: Recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann. Rheum Dis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/BOR.0000000000000625","article-title":"Treat-to-target in axial spondyloarthritis: Gold standard or fools\u2019 gold?","volume":"31","author":"Machado","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.rdc.2020.01.011","article-title":"Treat to Target in axial spondyloarthritis: Pros, cons, and future directions","volume":"46","author":"Liew","year":"2020","journal-title":"Rheum. Dis. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/annrheumdis-2011-200798","article-title":"How to define remission in ankylosing spondylitis?","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1002\/acr.20575","article-title":"Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S)","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","volume":"71","author":"Sieper","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/acr.23092","article-title":"Early disease activity or clinical response as predictors of long-term outcomes with certolizumab pegol in axial spondyloarthritis or psoriatic arthritis","volume":"69","author":"Deodhar","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","volume":"70","author":"Vastesaeger","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14712598.2020.1694900","article-title":"Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: Analysis of Czech ATTRA ankylosing spondylitis biologic registry","volume":"20","author":"Svoboda","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: Results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Valkenburg","year":"1984","journal-title":"Arthritis Rheum."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann. Rheum. Dis.."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"Assessment of SpondyloArthritis international S. Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states","volume":"77","author":"Machado","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1023\/B:EJEP.0000036572.00663.f2","article-title":"Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis","volume":"19","author":"Twisk","year":"2004","journal-title":"Eur. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00002281-200107000-00007","article-title":"Spondyloarthropathies in eastern Asia","volume":"13","author":"Feltkamp","year":"2001","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2009.11.015","article-title":"Clinical spectrum of ankylosing spondylitis in Korea","volume":"77","author":"Kim","year":"2010","journal-title":"Joint Bone Spine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ ACC\/ AACVPR\/ AAPA\/ ABC\/ ACPM\/ ADA\/ AGS\/ APhA\/ ASPC\/ NLA\/ PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/BOR.0000000000000284","article-title":"Treat-to-target as an approach in inflammatory arthritis","volume":"28","author":"Smolen","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_26","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice","volume":"33","author":"Arends","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/art.21588","article-title":"Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data","volume":"53","author":"Baraliakos","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s10067-018-4061-y","article-title":"Age determines response to anti-TNF\u03b1 treatment in patients with ankylosing spondylitis and is related to TNF\u03b1-producing CD8+ T cells","volume":"37","author":"Schramm","year":"2018","journal-title":"Clin. Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:52Z","timestamp":1760166172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/18\/4279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":28,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jcm10184279"],"URL":"https:\/\/doi.org\/10.3390\/jcm10184279","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]}}}